Member Contact: Dr Christophe Demaison
Position: Chief Executive Officer
Industry: Biotech & Pharmaceuticals
ENA Respiratory is a clinical stage, biotechnology company based in Melbourne. The company aims to transform the prevention of COVID-19 and other respiratory viral infections in populations at risk of severe complications. A spin-off of ENA Therapeutics (now renamed Axelia Oncology), ENA secured in March 2021, AU$32m Series A investment from the Minderoo Foundation, Brandon Capital Partners and Uniseed.